Coenzyme Q10 Supplementation Improves Adipokine Levels and Alleviates Inflammation and Lipid Peroxidation in Conditions of Metabolic Syndrome: A Meta-Analysis of Randomized Controlled Trials

Abstract

Evidence from randomized controlled trials (RCTs) suggests that coenzyme Q10 (CoQ10) can regulate adipokine levels to impact inflammation and oxidative stress in conditions of metabolic syndrome. Here, prominent electronic databases such as MEDLINE, Cochrane Library, and EMBASE were searched for eligible RCTs reporting on any correlation between adipokine levels and modulation of inflammation and oxidative stress in individuals with metabolic syndrome taking CoQ10. The risk of bias was assessed using the modified Black and Downs checklist, while the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool was used to evaluate the quality of evidence. Results from the current meta-analysis, involving 318 participants, showed that CoQ10 supplementation in individuals with metabolic syndrome increased adiponectin levels when compared to those on placebo (SMD: 1.44 [95% CI: −0.13, 3.00]; I2 = 96%, p < 0.00001). Moreover, CoQ10 supplementation significantly lowered inflammation markers in individuals with metabolic syndrome in comparison to those on placebo (SMD: −0.31 [95% CI: −0.54, −0.08]; I2 = 51%, p = 0.07). Such benefits with CoQ10 supplementation were related to its ameliorative effects on lipid peroxidation by reducing malondialdehyde levels, concomitant to improving glucose control and liver function. The overall findings suggest that optimal regulation of adipokine function is crucial for the beneficial effects of CoQ10 in improving metabolic health.

Coenzyme Q10 Supplementation Improves Adipokine Profile In Dyslipidemic Individuals: A Randomized Controlled Trial

“…A dose of 200 mg/d CoQ10 supplemented for 8 weeks increased serum adiponectin in individuals with type 2 diabetes [19]. The increase of adiponectin was parallel with the ameliorative effects on lipid peroxidation and glucose control [27]. Results from our present study were coincident with these trials.…”

Role of Coenzyme Q10 in Health and Disease: An Update on the Last 10 Years (2010–2020)

“…In contrast, different review papers published between 2015–2016 [ 10 , 11 , 12 , 13 , 14 ] validated claims that CoQ supplementation can significantly reduce morbidity and mortality in patients with heart failure or cardiovascular events; however, these articles also cautioned on the limitation of clinical studies informing on these positive outcomes. Recent reviewed evidence from our group [ 15 , 16 ] and others, including Suárez-Rivero and co-workers [ 17 ], as well as Dragan and colleagues [ 18 ], have explored the literature on the diverse therapeutic mechanisms that could be attributed to the beneficial effects of CoQ against CVD-related complications. These mainly involve its strong antioxidant and anti-inflammatory properties, especially the reduced form of CoQ (ubiquinol), which also appears to be less studied in comparison to its oxidized counterpart.…”

Age-related mitochondrial dysfunction as a key factor in COVID-19 disease

“…Further, in a model of carrageenan-induced inflammation in the air pouch, CoQ 10 , in combination with the known immunomodulator β-glucan, reduced leukocyte infiltration in lung, nitrite and proinflammatory cytokines IL1α and β levels (Vetvicka and Vetvickova, 2018). In humans, CoQ 10 supplementation significantly lower inflammation markers in individuals with metabolic syndrome (Dludla et al, 2020) or with diabetic nephropathy (Heidari et al, 2018). CoQ 10 supplementation also reduces the proinflammatory marker, β-defensin 2 (hBD2) indicating a reduction in inflammatory status associate with diabetes (Brauner et al, 2014).…”